Biotechnology M&A » By The Online Investor Staff, updated Thu., May. 9, 3:46 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
Slide #83. Charles River Laboratories International, Inc. — Accugenix, Inc.
Acquirer: |
Charles River Laboratories International, Inc. (NYSE:CRL) |
Acquiree: |
Accugenix, Inc. |
Details: |
Charles River Laboratories International, Inc. announced that it has acquired Accugenix, Inc. for approximately $17 million in cash. |
Charles River Laboratories International is a full service, non-clinical global drug development partner. Co. has laboratory animal medicine and science (research model technologies) to develop a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports its clients from target identification through non-clinical development. Co. also provides a suite of products and services to support its clients' manufacturing activities, including its contract development and manufacturing organization business. Co. has three reporting segments: Research Models and Services, Discovery and Safety Assessment and Manufacturing Solutions.
CRL SEC Filing Email Alerts Service
Open the CRL Page at The Online Investor »
Company Name: |
Charles River Laboratories International Inc. |
Website: |
www.criver.com |
Sector: |
Biotechnology |
Number of ETFs Holding CRL: |
83 |
Total Market Value Held by ETFs: |
$1.93B |
Total Market Capitalization: |
$12.08B |
% of Market Cap. Held by ETFs: |
15.97% |
|
Open the CRL Page at The Online Investor (in a new window) »
|
May 9, 2024 3:46 AM Eastern
Buy (3.20 out of 4)
40th percentile
|
|